6CM
CADL icon

683 Capital Management’s Candel Therapeutics CADL Stock Holding History

683 Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40,929
Closed -$208K – 278
2022
Q1 		$208K Hold
40,929
– – 0.01% 266
2021
Q4 		$320K Buy
+40,929
New +$397K 0.01% 262

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

683 Capital Management's CADL Position: Q2 2022 in Review

683 Capital Management sold out of Candel Therapeutics (CADL) in Q2 2022, closing a stake of 40,929 shares — an estimated $208K sold.

683 Capital Management first reported a position in CADL in Q4 2021 and held it in 2 quarters. The position peaked at $320K in Q4 2021. 23 funds tracked by Wall St. Rank hold CADL as of Q2 2022.

  • 683 Capital Management reported no remaining Candel Therapeutics position as of Q2 2022 after selling out during the quarter.
  • 683 Capital Management sold 40,929 Candel Therapeutics shares in Q2 2022, an estimated $208K.
  • 683 Capital Management first reported a position in Candel Therapeutics in Q4 2021 and held it in 2 quarters.
  • 683 Capital Management's Candel Therapeutics position peaked at $320K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2022.

Based on 683 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.